Phase II - Ozanezumab (GSK1223249)

Company

GlaxoSmithKline

Canadian Clinics Recruiting

To be announced. Ask your clinician for details.

Countries Involved

Australia
Belgium
Canada
France
Germany
Italy
Japan
Netherlands
South Korea
United Kingdom
United States

Trial Phase

Phase II – examining safety and potential efficacy

Drug Name

Ozanezumab (GSK1223249)

Trial Name

NOG112264

Route of Administration

Intravenous (IV)

Summary

Ozanezumab (GSK 1223249) is a drug that targets a protein called Neurite Outgrowth Inhibitor (Nogo-A). It is a monoclonal antibody, which is a substance that the body makes in immunity to prevent the action of a particular protein. Nogo-A blocks neurons from growing toward muscle once the connection has been made. When motor neurons degenerate and the connection becomes weakened, Nogo-A would work against keeping that nerve/muscle contact strong. Increased Nogo-A has been observed in muscle of people with ALS and ozanezumab delayed symptom onset and improved survival in ALS model mice. Thus, it is hoped that it will preserve muscle function and slow the rate of ALS progression in humans.